A growing body of evidence suggests that HDAC2-inhibiting drugs such as class I HDAC inhibitor, can act not only as standalone anti-cancer agents but also improve the therapeutic effect of ICIs in various types of solid cancers. This evidence concerns the gene HDAC9 and cancer.